Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)

Active, not recruiting · Phase 3 · NCT06297603

Conditions: Type 2 Diabetes

Research payments reported, 2025: $2.6M
U.S. investigators named: 37
Sites paid: 44
Planned or actual enrollment: 320

About the trial

Sponsor: Eli Lilly and Company
Tested: Retatrutide (drug), Placebo (drug)
Dates: Started 2024-03-15; completion 2026-11
Results posted: Not yet

The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and renal impairment, with inadequate glycemic control on basal insulin alone or a combination of basal insulin with or without metformin and/or sodium-glucose cotransporter-2 (SGLT2) inhibitor. The study will last about 14 months and may include up to 22 visits.

From ClinicalTrials.gov, last updated 2026-07-20. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Eli Lilly and Company reported $2.6M in research payments for this study in 2025 (78 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Encore Medical Research of Weston LLC $400,741
Mgcendo LLC $325,119
Altagracia Aurora Alcantara Gonzalez $149,158
Orita Clinical Research LLC $135,284
Ati Holdings LLC DBA Ati Worksite Solutions $129,053
Southern Endocrinology Associates PA $127,184
Texas Valley Clinical Research LLC $120,587
Care Institute LLC $108,825
Juno Research LLC $95,062
Apogee Clinical Research LLC $94,728
Darius A Schneider MD Apc Endotrials $94,005
University of North Carolina at Chapel Hill $84,850
Endocrine Ips PLLC $74,725
Healthy Mindset Intl DBA Diabetes & Endocrine Treatment Specialists $70,334
Nyc Research Inc $65,651
Clinre Inc $56,012
Preferred Primary Care Physicians Inc $52,772
Alliance Clinical Holdings LLC $47,724
Northeast Research Institute $45,865
Central State Research $42,531
Neighborhood Healthcare $42,269
Encore Medical Research, LLC $37,155
Cleveland Clinic, OH $26,959
Billings Clinic Hospital, MT $26,490
Velocity Clinical Research Inc $24,738
Hope Purchaser LLC DBA Hope Clinical Research LLC $23,732
N Texas Diabetes and Endocrine $21,541
Clinical Trial Source LLC $20,683
Neurology Clinic PC $15,218
$11,032
Providence St Mary $10,817
Hospital Metropolitano $10,064
Centro De Endocrinologia Del Este Csp $9,931
Ronald Reagan UCLA Medical Center, CA $8,548
Intend Research LLC $7,434
Lucas Research Inc $7,175
Clinical Research Institute of Arizona LLC $4,975
Care Access Research LLC $4,631
Research Foundation of State Univ of Ny $2,655
Cotton Oneil Msd of Stormont Vail Healthcare $1,512
Albany Medical College $570
Upstate Medical University $405
Diabetes and Endocrinology Consultants $331
Am Diabetes and Encrinology Center $252
Dallas Diabetes and Endo Research Center PA $105

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.

At a glance

About the trial

Industry funding

U.S. investigators named on this study

Sites paid to run it